Latest Charles River Laboratories Intl (CRL) Headlines
Charles River Aims To Be 'One-Stop Shop' With Buyout
at Investor's Business Daily - Thu Mar 13, 10:39AM CDT
Contract research organization Charles River Laboratories (CRL) said Thursday that it's agreed to buy the CRO business of Belgian drugmaker Galapagos NV. Charles River stock touched a more than five-year high in early trading on the stock market...
Charles River Laboratories acquires CRO services division of Galapagos for EUR129m cash
M2 - Thu Mar 13, 7:07AM CDT
Drug development company Charles River Laboratories International Inc (NYSE:CRL) announced today that it has entered into a definitive agreement to acquire the CRO (contract research organisation) services division of Galapagos NV (FRA: GXE.F) (OTC: GLPGF), which includes both Argenta and BioFocus.
3 Stocks Breaking Out on Big Volume
at The Street - Thu Mar 13, 5:00AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to EUR134 million
Thomson Reuters ONE - Thu Mar 13, 1:46AM CDT
-- Total cash consideration of up to EUR134 million
Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV
Business Wire - Thu Mar 13, 1:45AM CDT
--- Transaction Expected to be Accretive to Non-GAAP EPS by $0.10 in 2014 -
Insider Trading Alert - ETN, PCG And CRL Traded By Insiders
at The Street - Mon Mar 10, 12:00PM CDT
Stocks with insider trader activity include ETN, PCG and CRL
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Charles River Laboratories to Present at Cowen and Raymond James Conferences
Business Wire - Mon Mar 03, 7:30AM CST
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Cowen and Company 34th Annual Health Care Conference in Boston, Massachusetts on Tuesday, March 4th, at 10:00 a.m. ET, and the Raymond James 35th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 4th, at 10:25 a.m. ET. Management will present an overview of Charles River's strategic focus and business developments.
Insider Trading Alert - CRL, IDA And DAL Traded By Insiders
at The Street - Fri Feb 28, 9:45AM CST
Stocks with insider trader activity include CRL, IDA and DAL
NOVA Chemicals Reports 2013 Fourth Quarter and Full Year Results
Thomson Reuters ONE - Thu Feb 27, 7:38AM CST
Quintiles Transnational Holdings (Q) Jumps: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:57AM CST
Quintiles Transnational Holdings Inc. (Q) was a big mover last session, as the company saw its shares rise over 5% on the day.
Charles River Beats Earnings Estimates in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 9:15AM CST
Charles River Labs reported 4Q13 earnings (excluding special items) of 73 cents per share, beating the Zacks Consensus Estimate of 68 cents
CHARLES RIVER LABS
at Investor's Business Daily - Tue Feb 11, 5:34PM CST
CHARLES RIVER LABS (CRL), a research service provider, said Q4 revenue rose 4.3% to $289.2 mil, in line. EPS rose 14% to 73 cents, beating by 5 cents. It sees '14 EPS of $3-$3.10, below views for $3.20.
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2013 Results from Continuing Operations and Provides 2014 Guidance
Business Wire - Tue Feb 11, 3:30PM CST
--- Fourth-Quarter GAAP Earnings per Share of $0.40 and Non-GAAP Earnings per Share of $0.73 -
Will Zoetis (ZTS) Miss Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 11:50AM CST
Zoetis is set to report fourth quarter and full year 2013 results on Feb 11 before the opening bell.
BioTelemetry (BEAT) Soars: Stock Up 22.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 8:39AM CST
BioTelemetry, Inc. was a big mover last session, as its shares surged over 22% on the day.
19.6% Return Seen to Date on SmarTrend Charles River Laboratories Call (CRL)
Comtex SmarTrend(R) - Thu Jan 30, 9:44AM CST
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on October 18th, 2013 at $47.51. In approximately 3 months, Charles River Laboratories has returned 19.55% as of today's recent price of $56.80.
Healthways Up on Healthcare Deal Extension - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 29, 5:40PM CST
Healthways Up on the partnership deal extension with Essence Healthcare Deal Extension
Charles River Laboratories Schedules Fourth-Quarter 2013 Earnings and 2014 Guidance Release and Conference Call
Business Wire - Mon Jan 27, 3:15PM CST
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2013 financial results and provide 2014 financial guidance on Tuesday, February 11th, after the market closes. A conference call has been scheduled to discuss this information on Wednesday, February 12th, at 8:30 a.m. ET.
21.4% Return Seen to Date on SmarTrend Charles River Laboratories Call (CRL)
Comtex SmarTrend(R) - Thu Jan 23, 9:24AM CST
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on October 18th, 2013 at $47.51. In approximately 3 months, Charles River Laboratories has returned 21.36% as of today's recent price of $57.66.